Prothena Corporation plc
PRTA
Jodie situation report
Prothena Corporation plc's move is being confirmed by its market group.
No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NRIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind PRTA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BMYBristol-Myers Squibb CompanypartnerMay 7, 2026 ▾
“Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in partnership with Roche, coramitug currently being evaluated in the Phase 3 CLEOPATTRA clinica…”
NVONovo Nordisk A/SinvesteeFeb 27, 2026 ▾
“ATTR Amyloidosis Business Acquired by Novo Nordisk In July 2021, we announced that we and Novo Nordisk entered into a definitive purchase agreement under which Novo Nordisk acquired our clinical stage antibody coramitug and broader ATTR amyloidosis business.”
Depended on by
DNLIDenali Therapeutics Inc. Common StockcompetitorFeb 26, 2026 ▾
“Additionally, potentially disease modifying therapeutics are being developed by several large and specialty pharmaceutical and biotechnology companies, including Biogen/lonis, Arrowhead, Eli Lilly (including Prevail Therapeutics, its wholly owned subsidiary),…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PRTA is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.